ESMO Immuno-Oncology 2022

ESMO Immuno-Oncology 2022
07–09 December 2022 | Geneva, Switzerland
From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.

ESMO Immuno-Oncology 2022

ESMO Immuno-Oncology 2022
07–09 December 2022 | Geneva, Switzerland
From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.
Optimizing TILs as a novel immunotherapy strategy in metastatic melanoma 1:04
Optimizing TILs as a novel immunotherapy strategy in metastatic melanoma
Maartje Rohaan • 29 Nov 2022
Fianlimab and cemiplimab in patients with advanced melanoma 8:43
Fianlimab and cemiplimab in patients with advanced melanoma
Omid Hamid • 29 Nov 2022
What does the future hold for LAG-3 as a novel target in melanoma? 0:49
What does the future hold for LAG-3 as a novel target in melanoma?
Omid Hamid • 29 Nov 2022
Addressing and overcoming limitations in cancer vaccines 2:31
Addressing and overcoming limitations in cancer vaccines
Michael Nishimura • 28 Nov 2022
Omitting total lymph node dissection and adjuvant therapy in melanoma 2:12
Omitting total lymph node dissection and adjuvant therapy in melanoma
Irene Reijers • 30 Nov 2022
PRADO: personalized response-driven therapy in resectable stage III melanoma 2:24
PRADO: personalized response-driven therapy in resectable stage III melanoma
Irene Reijers • 30 Nov 2022
Assessing the role of PARP inhibitors and immunotherapy in ovarian cancer 2:38
Assessing the role of PARP inhibitors and immunotherapy in ovarian cancer
Anniina Färkkilä • 14 Dec 2022
Breast and gynecological cancer highlights at ESMO Immuno-Oncology 2022 1:02
Breast and gynecological cancer highlights at ESMO Immuno-Oncology 2022
Anniina Färkkilä • 14 Dec 2022
Overcoming resistance to PARP inhibition in ovarian cancer 1:22
Overcoming resistance to PARP inhibition in ovarian cancer
Anniina Färkkilä • 14 Dec 2022
Modulating the tumor microenvironment to enhance cancer vaccines 1:50
Modulating the tumor microenvironment to enhance cancer vaccines
Michael Nishimura • 28 Nov 2022
The impact of metastasectomy in patients with melanoma receiving TILs 3:00
The impact of metastasectomy in patients with melanoma receiving TILs
Maartje Rohaan • 29 Nov 2022
What role will TILs play in treating patients with melanoma? 0:51
What role will TILs play in treating patients with melanoma?
Maartje Rohaan • 29 Nov 2022
FOXC1 as a novel prognostic biomarker in immune checkpoint inhibitor therapy 3:39
FOXC1 as a novel prognostic biomarker in immune checkpoint inhibitor therapy
Partha Ray • 14 Dec 2022
The role of immunohistochemistry in assessing ICI efficacy 3:19
The role of immunohistochemistry in assessing ICI efficacy
Partha Ray • 14 Dec 2022
Developing a FOXC1-based immunohistochemistry assay for basal-like breast cancer 2:20
Developing a FOXC1-based immunohistochemistry assay for basal-like breast cancer
Partha Ray • 14 Dec 2022
Advances in utilizing neoadjuvant immunotherapy in melanoma 3:09
Advances in utilizing neoadjuvant immunotherapy in melanoma
Omid Hamid • 29 Nov 2022
The content of VJOncology is intended for healthcare professionals